Why Moderna Stock Is Falling Today
Shares of Moderna (NASDAQ: MRNA) were falling 4.7% lower as of 11:55 a.m. EDT on Wednesday. The decline came after the company reported that the first participant has been dosed in a phase 1/2 study evaluating its quadrivalent flu vaccine. However, the more likely reason for the stock slipping is that investors remain concerned about the potential impact of the coronavirus delta variant on sales of Moderna's COVID-19 vaccine.
Moderna's announcement about the first patient dosing with its experimental flu vaccine is good news. This could easily have served as a positive catalyst for the vaccine stock were it not for other worries on investors' minds.
Image source: Getty Images.
Source Fool.com
